C6K0
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its nam… Read more
Market Cap & Net Worth: C6K0 (C6K0)
C6K0 (F:C6K0) has a market capitalization of $254.27 Million (€247.71 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #16552 globally and #1712 in its home market, demonstrating a -6.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying C6K0's stock price €13.66 by its total outstanding shares 18133968 (18.13 Million).
C6K0 Market Cap History: 2026 to 2026
C6K0's market capitalization history from 2026 to 2026. Data shows growth from $254.27 Million to $254.27 Million (0.00% CAGR).
C6K0 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how C6K0's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of C6K0 by Market Capitalization
Companies near C6K0 in the global market cap rankings as of March 19, 2026.
Key companies related to C6K0 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
C6K0 Historical Marketcap From 2026 to 2026
Between 2026 and today, C6K0's market cap moved from $254.27 Million to $ 254.27 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €254.27 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of C6K0 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $254.27 Million USD |
| MoneyControl | $254.27 Million USD |
| MarketWatch | $254.27 Million USD |
| marketcap.company | $254.27 Million USD |
| Reuters | $254.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.